{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Journal highlights with Dr. David Henry: Managing hematologic conditions in pregnancy, combo for elderly AML, genomics in DLBCL, and COVID-19 updates","description":"In this episode, host David H. Henry, MD, highlights some recent articles from Blood, the Journal of Clinical Oncology, and the New England Journal of Medicine. Blood  How I Treat series on hematologic complications in pregnancy. https:\/\/bit.ly\/3fr5nV8 Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia. https:\/\/bit.ly\/3nQvhF6  Journal of Clinical Oncology  Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. https:\/\/bit.ly\/3maTOE4  Related Blood &amp;amp; Cancer episode: Cancer and hepatitis B virus: ASCO's recommendations for HBV screening, monitoring for reactivation, and how to treat patients. https:\/\/bit.ly\/3m0jjrF   Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy. https:\/\/bit.ly\/372FFCB Chemotherapy and COVID-19 Outcomes in Patients With Cancer. https:\/\/bit.ly\/35WRLOi  Related Blood &amp;amp; Cancer episodes: Studying cancer patients with COVID-19: NCCAPS and CCC19. https:\/\/bit.ly\/3pYl2Au TERAVOLT registry sheds light on patients with thoracic cancers and COVID-19. https:\/\/bit.ly\/2URdwJh   Diffuse Large B-Cell Lymphoma\u2019s New Genomics: The Bridge and the Chasm. https:\/\/bit.ly\/36XdGnY  New England Journal of Medicine  Osimertinib in Resected EGFR-Mutated Non\u2013Small Cell Lung Cancer. https:\/\/bit.ly\/2J5q7FQ Humoral Immune Response to SARS-CoV-2 in Iceland. https:\/\/bit.ly\/2USw7ET Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. https:\/\/bit.ly\/39aM0ia Remdesivir for the Treatment of COVID-19 \u2013 Final Report. https:\/\/bit.ly\/375dYJk Remdesivir for 5 or 10 Days in Patients with Severe COVID-19. https:\/\/bit.ly\/2IZJ7Wq  Disclosures: Dr. Henry has no relevant disclosures. *&amp;nbsp; *&amp;nbsp; * For more MDedge Podcasts, go to mdedge.com\/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd ","author_name":"Blood &amp; Cancer","author_url":"https:\/\/www.mdedge.com\/podcasts\/blood-cancer","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/16924649\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/984545\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/16924649"}